Evidence map›Paper›PMID 37232349›Full record

ArticleMolecular medicine reports2023

Rita Adubeiro Lourenço, Miguel Lança, Octávia Monteiro Gil, Joana Cardoso, Teresa Lourenço, José B Pereira-Leal, António Sebastião Rodrigues, José Rueff, Susana Nunes Silva

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Rita Adubeiro Lourenço *ToxOmics, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa; 1150‑082 Lisbon, Portugal.
Miguel Lança *ToxOmics, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa; 1150‑082 Lisbon, Portugal.
Octávia Monteiro GilCenter for Nuclear Sciences and Technologies, Instituto Superior Técnico, Universidade de Lisboa, 2695‑066 Bobadela, Loures, Portugal.
Joana CardosoOphiomics‑Precision Medicine, 1600‑514 Lisbon, Portugal.
Teresa LourençoOphiomics‑Precision Medicine, 1600‑514 Lisbon, Portugal.
José B Pereira-LealOphiomics‑Precision Medicine, 1600‑514 Lisbon, Portugal.
António Sebastião RodriguesToxOmics, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa; 1150‑082 Lisbon, Portugal.
José RueffToxOmics, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa; 1150‑082 Lisbon, Portugal.
Susana Nunes SilvaToxOmics, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa; 1150‑082 Lisbon, Portugal.
Universidade Nova de Lisboa · PTUniversity of Lisbon · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic testing for susceptibility genes through next‑generation sequencing (NGS) has become a widely used technique. Using this, a number of genetic variants have been identified, several of which are variants of unknown significance (VUS). These VUS can either be pathogenic or benign. However, since their biological effect remains unclear, functional assays are required to classify their functional nature. As the use of NGS becomes more mainstream as a diagnostic tool in clinical practice, the number of VUS is expected to increase. This necessitates their biological and functional classification. In the present study, a VUS was identified in the

Indexed as

Breast NeoplasmsOvarian NeoplasmsBRCA1 ProteinBRCA2 ProteinDNA DamageDNA RepairFemaleGenes, BRCA1Genetic Predisposition to DiseaseGenetic TestingHumansBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA1breast cancerfunctional analysis of VUSgenotoxic challengenext‑generation sequencingvariants of unknown significance (VUS)

Identifiers

PMID37232349
PMCPMC10280555
OpenAlexW4378348024

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.